Digital health startups raised $7.4 billion in the first half of 2026, up from $6.4 billion in the first half of 2025, according to Rock Health's H1 2026 market overview. Read as a single headline, that looks like a recovery. Read as a distribution, it looks like something narrower and more uncomfortable for most founders: the market did not get healthier, it got more concentrated.
I have sat on both sides of this table, as an operator raising and as an investor reviewing decks, and the number that matters is never the aggregate. It is the shape of the curve underneath it.
Why the headline number is misleading you
Modern Healthcare's coverage of the Rock Health data makes the mechanism explicit: mega deals, rounds of $100 million or more, are carrying a disproportionate share of total capital. A market can post a rising topline while the number of companies that actually get funded keeps falling. CB Insights' Q2 2026 State of Digital Health report found global digital health deal activity fell to 228 deals in the quarter, a decade low, down 36 percent quarter over quarter and roughly two-thirds below the Q2 2022 peak of 688 deals. Median deal sizes are rising precisely because fewer companies are clearing the bar to get any deal at all.
That combination, fewer deals plus bigger checks, is not a broad recovery. It is a flight to quality inside a shrinking pool of qualifying companies, and it changes how you should plan a raise in 2026.
What is actually pulling the capital
Three forces are doing almost all the work:
- AI is the entry ticket, not a feature. Carta's Q1 2026 State of Private Markets found more than 60 percent of all venture capital going to AI-labeled companies in the quarter, creating what Carta calls a valuation gap between AI and non-AI startups in the same sector.
- Mega rounds are propping up the average. A handful of scaled, AI-native platforms with signed enterprise contracts are absorbing checks that used to be spread across a dozen smaller Series Bs.
- Investors are underwriting distribution, not just technology. The diligence bar has shifted from "does the model work" to "who already pays for this and at what renewal rate."
The benchmark table founders should actually use
| Stage | H1 2025 pattern | H1 2026 pattern |
|---|---|---|
| Seed | Broad, many small checks | Narrower, higher bar on early signed pilots |
| Series A | ARR + roadmap credible | Signed enterprise contract expected, not aspirational |
| Growth ($100M+) | Rare | Carrying a growing share of total dollars |
| Deal count | Higher | Decade-low quarterly deal counts (CB Insights) |
What this means if you are raising this year
Do not benchmark yourself against the aggregate number. $7.4 billion sounds like an open market. The deal count tells you the actual odds, and they are worse than the headline implies for anyone without a signed customer.
Lead with a contract, not a roadmap. The mega-deal concentration is a signal that investors are paying for proof of commercial pull, not for a compelling category thesis. If you do not have a signed health system, payer or employer contract, your fundraising timeline should assume a longer cycle and a smaller initial check than the market average suggests.
Expect your comparable set to be smaller and stranger. With fewer deals happening, the comps an investor uses to price you are increasingly the mega-rounds that made headlines, which are not comparable to an early-stage company at all. Bring your own comp set, built from real Series A and B data, not from the $100 million rounds that dominate the press cycle.
Watch deal count, not dollar totals, as your leading indicator. Aggregate funding is a lagging, distorted number. Quarterly deal count by stage is the number that tells you whether the market for a company like yours is actually opening or closing.
The 2026 digital health capital market is not undersupplied with money. It is oversupplied with capital chasing a small number of companies that have already de-risked the commercial question. Getting into that group before you raise, not after, is the entire strategy.
